Intratympanic Administration of N-acetylcysteine for Protection of Cisplatin-induced Ototoxicity : Clinical Trial: Intratympanic Injection of N-acetylcysteine for Protection of Cisplatin-induced Ototoxicity
This is a monocentric, randomized, controlled, open label phase IV superiority trial.After signing the informed consent form and upon the confirmation of the patient eligibility, patients will be randomized 1:1 to the experimental arm (NAC + Cisplatin) or the standard arm (Cisplatin).The primary objective of this trial is to evaluate the protecting effect of Lysomucil® 10% against Cisplatin-induced ototoxicity. In this case, we will evaluate its effect through the transtympanic administration in both ears..
| Medienart: |
|
|---|
Klinische Studie| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
ClinicalTrials.gov - (2023) vom: 24. Okt. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
610 |
|---|
| Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: January 13, 2020, Last downloaded: ClinicalTrials.gov processed this data on November 01, 2023, Last updated: November 01, 2023 |
|---|
| Study ID: |
NCT04226456 |
|---|---|
| Veröffentlichungen zur Studie: |
|
| fisyears: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
CTG003267539 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | CTG003267539 | ||
| 003 | DE-627 | ||
| 005 | 20231101010441.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210408s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)CTG003267539 | ||
| 035 | |a (UBBS_Klinische_Studien)NCT04226456 | ||
| 035 | |a (UBBS_Klinische_Studien)CHUB-NAC | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Intratympanic Administration of N-acetylcysteine for Protection of Cisplatin-induced Ototoxicity |b Clinical Trial: Intratympanic Injection of N-acetylcysteine for Protection of Cisplatin-induced Ototoxicity |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: January 13, 2020, Last downloaded: ClinicalTrials.gov processed this data on November 01, 2023, Last updated: November 01, 2023 | ||
| 520 | |a This is a monocentric, randomized, controlled, open label phase IV superiority trial.After signing the informed consent form and upon the confirmation of the patient eligibility, patients will be randomized 1:1 to the experimental arm (NAC + Cisplatin) or the standard arm (Cisplatin).The primary objective of this trial is to evaluate the protecting effect of Lysomucil® 10% against Cisplatin-induced ototoxicity. In this case, we will evaluate its effect through the transtympanic administration in both ears. | ||
| 650 | 2 | |a Hearing Loss | |
| 650 | 2 | |a Deafness | |
| 650 | 2 | |a Tinnitus | |
| 650 | 2 | |a Ototoxicity | |
| 650 | 2 | |a Hearing Loss, Bilateral | |
| 650 | 4 | |a Study Type: Interventional | |
| 650 | 4 | |a Recruitment Status: Terminated | |
| 650 | 4 | |a Phase: Phase 4 | |
| 650 | 4 | |a 610 | |
| 773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2023) vom: 24. Okt. |
| 773 | 1 | 8 | |g year:2023 |g day:24 |g month:10 |
| 856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT04226456 |z kostenfrei |3 Volltext |
| 912 | |a GBV_CTG | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 24 |c 10 | ||